Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia

Archives of General Psychiatry

Volumn 67, Issue 1, 2010, Pages 9-16

  Rasmussen, Hans ^a,b   Erritzoe, David ^b   Andersen, Rune ^a   Ebdrup, Bjorn H ^a   Aggernaes, Bodil ^a   Oranje, Bob ^a   Kalbitzer, Jan ^b   Madsen, Jacob ^b   Pinborg, Lars H ^b   Baaré, William ^c   Svarer, Claus ^b   Lublin, Henrik ^a   Knudsen, Gitte M ^b   Glenthoj, Birte ^a  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALTANSERIN; ALTANSERIN FLUORINE F 18; FLUORINE 18; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; KETANSERIN; SEROTONIN;

ADULT; ARTICLE; ATTENTION; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG RECEPTOR BINDING; FEMALE; FRONTAL CORTEX; HUMAN; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIA; UNIVERSITY HOSPITAL; BRAIN; COMPARATIVE STUDY; FRONTAL LOBE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CASE-CONTROL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; FRONTAL LOBE; HUMANS; KETANSERIN; MALE; NEUROPSYCHOLOGICAL TESTS; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SEROTONIN;

EID: 73649110630     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.176     Document Type: Article

References (60)

1. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm. 1991;85(1):19-29.
2. Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 1979; 36(9):927-934.
3. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996;15(5):442-455.
4. 2A receptors in schizophrenia. Schizophr Res. 1996;21(3):133-139.
5. 2A receptors in Brodmann's area 9 from schizophrenic subjects: a pathological or pharmacological phenomenon? Mol Chem Neuropathol. 1998;34(2-3):133-145.
6. A receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem. 1999;72(4):1593-1599.
7. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry. 1997;42(7):529-545.
8. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry. 1993;50(10):810-818.
9. 2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett. 2005;379(3): 164-168.
10. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry. 1986;21(14):1407-1414.
11. 2A receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr Res. 2000;44(1):35-45.
12. Dean B, Hayes W, Opeskin K, Naylor L, Pavey G, Hill C, Keks N, Copolov DL. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav Brain Res. 1996;73(1-2):169-175.
13. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993;8(4):315-336.
14. Reynolds GP, Rossor MN, Iversen LL. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl. 1983;18:273-277.
15. Whitaker PM, Crow TJ, Ferrier IN. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry. 1981;38(3):278-280.
16. Dean B, Crossland N, Boer S, Scarr E. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr Res. 2008;104 (1-3):185-197.
17. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353-359.
18. 2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-246.
19. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15(1)(suppl 1):19S-23S.
20. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(7):1159-1172.
21. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry. 2000;57(9):907-913.
22. Gur RC, Ragland JD, Moberg PJ, Bilker WB, Kohler C, Siegel SJ, Gur RE. Computerized neurocognitive scanning, II: the profile of schizophrenia. Neuropsychopharmacology. 2001;25(5):777-788.
23. Conklin HM, Curtis CE, Calkins ME, Iacono WG. Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia. 2005;43(6):930-942.
24. Jindal RD, Keshavan MS. Neurobiology of the early course of schizophrenia. Expert Rev Neurother. 2008;8(7):1093-1100.
25. 2A/2B/2C receptors on memory formation: simple agonism, antagonism, or inverse agonism? Cell Mol Neurobiol. 2002;22(5-6): 675-688.
26. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl). 2004;174(1):17-24.
27. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical anti-psychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004; 114(6):593-611.
28. Tyson PJ, Laws KR, Flowers KA, Tyson A, Mortimer AM. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry Clin Neurosci. 2006;60(4):473-479.
29. 2A receptors in working memory. J Neurosci. 2002;22(7):2843-2854.
30. 2A receptor blockade in healthy volunteers pretreated with an SSRI. J Psychopharmacol. 2007;21(5):477-485.
31. 18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry. 1999; 156(1):72-78.
32. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 2000; 66(25):2455-2464.
33. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res. 1998;31(1):13-17.
34. 18F]setoperone. Am J Psychiatry. 2000;157(6):1016-1018.
35. 2A receptor binding in neuroleptic-naive first-episode schizo-phrenic patients. Neuropsychopharmacology. 2008;33(10):2435-2441.
36. 18F]altanserin in human and rodent. Nucl Med Biol. 1999;26(6):601-608.
37. 2A receptor antagonists altanserin and MDL 100907. Synapse. 2005;58(4):249-257.
38. 18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging. 2007;34(6):910-915.
39. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N; Schedules for Clinical Assessment in Neuropsychiatry. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990; 47(6):589-593.
40. Erritzoe D, Frokjaer VG, Haugbol S, Marner L, Svarer C, Holst K, Baaré WF, Rasmussen PM, Madsen J, Paulson OB, Knudsen GM. Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use [published correction appears in Neuroimage. 2009;47(2):780]. Neuroimage. 2009;46(1): 23-30.
41. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
42. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30-46.
43. Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85(7):399-402.
44. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med. 1991;32(12):2266-2272.
45. 18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab. 2003; 23(8):985-996.
46. 2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage. 2004;21(3):1105-1113.
47. 123I]iomazenil. Eur J Pharmacol. 1993;249(1):43-51.
48. Willendrup P, Pinborg LH, Hasselbalch SG, Adams KH, Stahr K, Knudsen GM, Svarer C. Assessment of the precision in co-registration of structural MR-images and PET-images with localized binding. Int Congr Ser. 2004;1265:275-280. doi:10.1016/j.ics.2004.04.065.
49. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Frøkjaer VG, Holm S, Paulson OB, Knudsen GM. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005; 24(4):969-979.
50. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998; 17(1):87-97.
51. Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12(4):571-583.
52. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, Alfano B, Brunetti A, Baron JC, Salvatore M. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med. 2004; 45(2):192-201.
53. Grubbs FE. Procedures for detecting outlying observations in samples. Technometrics. 1969;11(1):1-21.
54. Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baaré W, Svarer C, Madsen J, Lublin H, Knudsen GM, Glenthoj BY. Cortical and subcortical 5-HT(2A) receptor binding in neuroleptic-naive first-episode schizo-phrenic patients. Neuropsychopharmacology. 2008;33(10):2435-2441.
55. 2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl). 2005;210(5-6):519-523.
56. 2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl). 2008;195(4):579-590.
57. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28(suppl 2):1-16.
58. 2/3 receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry. 2006;60(6):621-629.
59. 2A receptors is unaltered after citalopram and pindolol challenge. J Cereb Blood Flow Metab. 2004;24(9):1037-1045.
60. 2A receptors by agonists and antagonists. Brain Res Bull. 2001;56(5):441-451.